To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. KOCHETKOV, N.A. SHATALOVA, M.V. KLEPIKOVA, T.V. FILIPPOVA, O.D. OSTROUMOVA
Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Health of the Russian Federation, Moscow

Place of publication:
THERAPY No. 8 (70) 2023

Abstract:
Abstract. Chronic cerebral ischemia (CCI) is one of the most common neurological pathologies. Its development is influenced by many factors, among which arterial hypertension (AH) occupies a special place. CCI contributes to cognitive impairment, negatively affects quality of life, and leads to motor and psychoemotional disorders. In terms of treatment, neuroprotectors play an important role, in particular, the use of ethylmethylhydroxypyridine succinate (Mexidol®^,NPK Pharmasoft LLC, Russia), which has a multimodal effect and confirms its high efficacy in numerous clinical trials. The evidence base for ethylmethylhydroxypyridine succinate, obtained including in the MEMO study, indicates a particularly high efficacy in patients with CCI and hypertension: Mexidol®^{significantly} improves cognitive function, reduces anxiety and asthenia, and improves quality of life. Taking this into account, the drug can be recommended for use in the complex therapy of chronic cerebral ischemia, especially in patients with hypertension. Key words: chronic cerebral ischemia, ethylmethylhydroxypyridine succinate, Mexidol®^,arterial hypertension, cognitive functions.